LC-MS/MS CHARACTERIZATION OF FORCED DEGRADATION PRODUCTS OF TUCATINIB, A NOVEL TYROSINE KINASE INHIBITOR: DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD

Authors

  • S. K. REEHANA Department of Pharmaceutical Analysis, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur 522510, Andhra Pradesh, India
  • K. SUJANA Department of Pharmaceutical Analysis, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur 522510, Andhra Pradesh, India

DOI:

https://doi.org/10.22159/ijap.2022v14i1.43252

Keywords:

LC-MS/MS, tucatinib, method development, validation, degradation pathways

Abstract

Objective: The current study focused on the development, validation, and characterization of forced degradation products using LC-MS/MS.

Methods: A simple, selective, validated and well-defined isocratic HPLC methodology for the quantitative determination of Tucatinib at a wavelength of 239 nm. An isocratic elution of samples was performed on an Inertsil ODS (250x4.6mm,5m) column with a mobile phase of 70:30v/v Acetonitrile and formic acid (0.1%) delivered at a flow rate of 1.0 mL/min. MS/MS was used to characterize degradation products formed in the forced degradation study.The validation and characterization of forced degradation products were performed in accordance with ICH guidelines.

Results: Over the concentration range of 5-100μg/ml, a good linear response was obtained. Tucatinib's LOD and LOQ were determined to be 0.05 and 0.5, respectively. According to standard guidelines, the method was quantitatively evaluated in terms of system suitability, linearity, precision, accuracy, and robustness, and the results were found to be within acceptable limits. The drug was degraded under acidic, alkaline, and reduction conditions in forced degradation studies.

Conclusion: The method was found to be applicable for routine tucatinib analysis. Because no LC-MS/MS method for estimating tucatinib and its degradation products has been reported in the literature. There is a need to develop a method for studying the entire tucatinib degradation pathway.

Downloads

Download data is not yet available.

References

Gross Stefan, Rahal Rami, Stransky Nicolas, et al. Targeting cancer with kinase inhibitors. J Clin Invest 2015;125:1780–9.

Jänne Pasi A, Gray Nathanael, Settleman Jeff. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009;8:709–23.

Mitri Z, Constantine T, O'Regan R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract 2012; 2012:743193.

Roy V, Perez EA. Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist 2009;14:1061–9.

Laetitia Seguin, Shumei Kato, Aleksandra Franovic, et al. An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol 2014.

Zink Daniele, Fische Andrew H, Nickerson Jeffrey A. Nuclear structure in cancer cells. Nat Rev Cancer 2004;4:677–87.

Vlastaridis Panayotis, Papakyriakou Athanasios, Chaliotis Anargyros, et al. The Pivotal Role of Protein Phosphorylation in the Control of Yeast Central Metabolism. G3 (Bethesda) 2017;7:1239–49.

Sharma Saumya, Guthrie Patrick H, Chan Suzanne S, et al. Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc Res 2007;76:71–80.

Yu J, Sun X, Goie J, Zhang Y. Regulation of Host Immune Responses against Influenza A Virus Infection by Mitogen-Activated Protein Kinases (MAPKs). Microorganisms 2020;8: 1067.

Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biolo Rev 2011;75:50–83.

Hill MM, Hemmings BA. Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol Ther 2002;93:243–51.

Xie J, Weiskirchen R. What Does the AKT Stand for in the Name AKT Kinase? Some Historical Comments. Front Oncol 2020;10:1329.

Lademann Juergen, Martschick Anja, Kluschke Franziska, et al. Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy. Skin Pharmacol Physiol 2014;27:66–70.

Rosenbeck L, Kiel PJ. Images in clinical medicine. Palmar-plantar rash with cytarabine therapy. N Engl J Med 2011;364:e5.

Manov I, Motanis H, Frumin I, Iancu TC. Hepatotoxicity of anti-inflammatory and analgesic drugs: ultrastructural aspects. Acta Pharmacol Sin 2006;27:259–72.

Brocklehurst P, Tickle M, Glenny AM, Lewis MA, et al. Systemic interventions for recurrent aphthous stomatitis (mouth ulcers). Cochrane Database Syst Rev 2012;9: CD005411.

Lawton CL. Obesity: a disorder of appetite. Practical Diabetes International 1993;10:10–2. http:// doi:10.1002/pdi.1960100105

Viniol A, Keunecke C, Biroga T, Stadje R, et al. Studies of the symptom abdominal pain--a systematic review and meta-analysis. Fam Pract 2014;31:517–29.

Potturi Ramadevi, Kantipudi Rambabu. Bio analytical method development and validation for Ezetimibe and Pitavastain and its applications to pharmacokinetic studies in Rabbit plasma by using LCMS/MS. Int J Res Pharm Sci 2020;11:7854-62.

Asha Eluru, Surendra Babu K. Bio analytical method development and validation for Aplidine in rat plasma and their pharmacokinetic studies by LCMS. World Journal of Pharmacy and Pharmaceutical Sciences 2019;8:1201-9.

D. Ramchandran, Anita Kethipalli, Mannam Krishnamurthy. Bio analytical method development and validation of Daunorubicin and Cytrarabine in rat plasma by LC-MS/MS and its application in pharmacokinetic studies. J Pharm Sci & Res 2020;12:381-6.

Shalini K, Ilango K. Development, Evaluation and RP-HPLC method for simultaneous estimation of Quercetin, Ellagic acid and Kaempferol in a poly herbal formulation. Int J App Pharm 2021; 13: 183-92.

Malak Y, Al-Bathish A. A, Gazy M. K. El-Jamal. Rp-hplc and chemometric methods for the determination of two anti-diabetic mixtures;metformin hydrochloride-canagliflozin and metformin hydrochloride-gliclazide in their pharmaceutical formulation. Int J Pharm Pharm Sci 2020;12:83-94.

Sri Girija K, Bikshal Babu K, Venkateswara Rao A. A new high performance liquid chromatography method for the separation and simultaneous quantification of Eptifibatide and its impurities in pharmaceutical injection formulation. Int J App Pharm 2021;13:165-72.

V L N Balaji Gupta T, Venkateswara Rao B, Kishore Babu B. RP-HPLC (stability indicating) based assay method for the simultaneous estimation of Doravirine, Tenofovir Disoproxil Fumarate and Lamivudine. Int J App Pharm 2021;13:153-9.

International conference on the harmonization. ICH harmonized tripartite guideline. Validation of analytical procedures: Text and methodology Q2(R1);2005.

Manoranjani M. A study of method development, validation and forced degradation for simultaneous quantification of Cisplatin and Fluorouracil in bulk and pharmaceutical dosage form by RP-HPLC. J Pharm Sci & Res 2021;13:155-61.

Hemanth Kumar A K, Sudha V, Vijayakumar A, Padmapriyadarsini C. Simultaneous method for the estimation of Bidaquiline and Delamanid in human plasma using high performance liquid chromatography. Int J Pharm Pharm Sci 2021;13:36-40.

Shanmugasundaram P, Kamarapu S K. RP-HPLC method for the simultaneous estimation and validation of amlodipine besylate and atenolol in bulk and tablet dosage form in biorelevant dissolution medium (Fassif). Research J Pharm and Tech 2017;10:3379-85.

Sruthi A, Uttam Prasad P. Stability indicating method development and validation of Fimasartan by reverse phase high performance liquid chromatography in bulk and pharmaceutical dosage form. Asian J Pharm Clin Res 2021;14:138-46.

Narasimha S. Lakka, Chandrasekar Kuppan, Kona S. Srinivas, Raviteja Yarra. Separation and characterization of new forced degradation products of Dasatinib in tablet dosage formulation using LC-MS/MS and stability indicating HPLC methods. Chromatographia 2020;83:947-62.

Balasaheb B Chavan, Vijaya jyothi P, Pradipbhai D Kalariya, et al. Alcaftadine: Selective separation and characterization of degradation products by LC-QTOF-MS/MS. Chromatographia 2018;81:631-8.

Published

22-11-2021

How to Cite

REEHANA, S. K., & SUJANA, K. (2021). LC-MS/MS CHARACTERIZATION OF FORCED DEGRADATION PRODUCTS OF TUCATINIB, A NOVEL TYROSINE KINASE INHIBITOR: DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD. International Journal of Applied Pharmaceutics, 14(1). https://doi.org/10.22159/ijap.2022v14i1.43252

Issue

Section

Original Article(s)